Atenuación del fenómeno del polimorfismo en la formulación de comprimidos de indometacina
Keywords:
Indometacina, Polimorfismo, Formulación, ComprimidosAbstract
En un fármaco policristalino como es Indometacina, se ha llevado a cabo una investigación sobre una formulaciónalternativa que emplee el polimorfo II de esta especie química en vez del polimorfo I, oficial éste en la farmacopeaamericana. Además, se ha formulado en comprimidos como alternativa a la monografía oficial de cápsulas en lamisma farmacopea. Su formulación en comprimidos evita las diferencias que puedan existir inicialmente según elpolimorfo empleado. Se concluye que ambos polimorfos se pueden usar indistintamente bajo la forma farmacéuticade comprimidos.Downloads
References
Borka L. The polymorphism of Indomethacine. New modifications, their melting behaviour and solubility. Acta Pharm Suecica 1974; 11: 295-301.
Del Río LA. Estudio de preformulacion para el desarrollo de comprimidos de indometacina como substancia policristalina. Ars Pharm 2002. En prensa.
The United States Pharmacopoeia. 24th edition, p.874. The United States Pharmacopoeial Convention, Inc., Rockville, MD 1999.
Parfitt K. Martindale. The complete drug reference. 32th edition, p.46. The Pharmaceutical Press. Massachusetts 1999.
Del Río LA. Influencia de la reposición en la estabilidad, tiempo de disgregación y velocidad de disolución en comprimidos de nueva formulación de Indometacina. Tesina de Grado de Licenciado, pp.40-45. Facultad de Farmacia, Universidad Complutense, Madrid 1984
Food and Drug Administration. Guidance for Industry : Dissolution Testing of Inmediate Release Solid Oral Dosage Forms. http://www.fda.gov/cder/guidance.htm 1997.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).